KELVIN MEDICAL INC

As of March 31, 2018, KELVIN MEDICAL INC carries a market capitalization of 107.51M, placing it among publicly traded companies globally. Its enterprise value stands at 107.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2018, KELVIN MEDICAL INC has 67.30M shares outstanding.

These figures are as of March 31, 2018.

As of March 31, 2018, KELVIN MEDICAL INC maintains a current ratio of 0.85, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended March 31, 2018, KELVIN MEDICAL INC generated - - in revenue and converted that into -162,127.00 in net income, yielding earnings per share of 0.00. EBITDA reached -162,127.00, while operating income came in at -102,127.00.

These figures are as of March 31, 2018. Total book value stands at -6,293.00, with working capital of -6,293.00 providing operational flexibility.

KELVIN MEDICAL INC produced -76,231.00 in operating cash flow over the twelve months ended March 31, 2018.

These figures cover the twelve months ended March 31, 2018. Free cash flow yield is negative at -0.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.10, meaning KELVIN MEDICAL INC raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of March 31, 2018, KELVIN MEDICAL INC has an Altman Z-Score of 1,486.90, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.